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ABSTRACT
Objective: To develop, pilot and refine a decision aid
(ahead of a randomised trial evaluation) for women
around age 50 facing their initial decision about
whether to undergo mammography screening.
Design: Two-stage mixed-method pilot study
including qualitative interviews (n=15) and a
randomised comparison using a quantitative survey
(n=34).
Setting: New South Wales, Australia.
Participants: Women aged 43–59 years with no
personal history of breast cancer.
Interventions: The decision aid provides evidence-
based information about important outcomes of
mammography screening over 20 years (breast cancer
mortality reduction, overdetection and false positives)
compared with no screening. The information is
presented in a short booklet for women, combining
text and visual formats. A control version produced for
the purposes of comparison omits the overdetection-
related content.
Outcomes: Comprehension of key decision aid
content and acceptability of the materials.
Results: Most women considered the decision aid
clear and helpful and would recommend it to others.
Nonetheless, the piloting process raised important
issues that we tried to address in iterative revisions.
Some participants found it hard to understand
overdetection and why it is of concern, while there was
often confusion about the distinction between
overdetection and false positives. In a screening
context, encountering balanced information rather than
persuasion appears to be contrary to people’s
expectations, but women appreciated the opportunity
to become better informed.
Conclusions: The concept of overdetection is
complex and new to the public. This study highlights
some key challenges for communicating about this
issue. It is important to clarify that overdetection
differs from false positives in terms of its more serious
consequences (overtreatment and associated harms).
Screening decision aids also must clearly explain their
purpose of facilitating informed choice. A staged
approach to development and piloting of decision aids
is recommended to further improve understanding of
overdetection and support informed decision-making
about screening.
INTRODUCTION
Recent changes to international policy and
practice have sought to promote greater
involvement of patients and citizens in
healthcare decision-making.1–3 It is argued
that, just as patients may choose between
treatment options, people offered medical
screening should have the opportunity to
make informed decisions about whether to
participate.4 5 Supporting informed choice
about screening requires clear, balanced
information on beneﬁts and harms,6 7 as
reﬂected in new approaches to screening
information provision.8 One way to facilitate
informed decision-making is through the use
of decision aids—resources designed for
patients or citizens facing speciﬁc decisions
about treatment or screening. Decision aids
provide evidence-based information about
the beneﬁts and harms of healthcare
options, and their capacity to improve users’
knowledge about the options has been
demonstrated via randomised trials in a
variety of healthcare settings.9
Strengths and limitations of this study
▪ The strengths of this project include the staged,
mixed-methods approach to developing and
evaluating the decision aid, combining both
qualitative and quantitative data.
▪ The iterative pilot-testing process enabled us to
explore women’s responses to successive drafts,
identify problematic aspects, and revise the
materials to clarify misconceptions.
▪ Decisions about initial design and subsequent
modifications were undertaken by an experienced
multidisciplinary team with input from layper-
sons and independent experts.
▪ Some participants in stage 1 pilot interviews
already had breast screening experience, thus
differing from our ultimate intended audience,
and this may have affected their responses.
Stage 2 participants were members of the target
population facing real-life decisions.
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One of the main harms of mammography screening is
overdetection (or overdiagnosis) leading to treatment of
breast cancers that would not otherwise present clinic-
ally or cause problems in a woman’s life. Overdetection
results in harm to emotional and physical health, both
in the short and long terms. 10 11 However, information
about overdetection has been lacking from materials
distributed by breast screening programmes world-
wide.12–14 Furthermore, there is little evidence regarding
how best to convey this novel information to the public.
In a qualitative study,15 we examined how women aged
40–79 responded to information about overdetection,
exploring its potential inﬂuence on decision-making
about breast cancer screening and treatment. The study
also highlighted challenges in explaining this new and
counterintuitive concept, and conﬁrmed that women
were participating in screening (or not) without
knowing about the risk of overdetection. After our
face-to-face explanation, focus group discussions and
clariﬁcation of queries, most participants demonstrated
a reasonable understanding of the issue. Although sur-
prised, women valued the information and felt that it
ought to be provided when screening is offered15—ﬁnd-
ings echoed in a similar UK study.16 This suggests that
informed decision-making should be possible for poten-
tial screening participants, when they are provided with
good information. The challenge remaining was to
convert a meaningful explanation of overdetection into
a written format and test whether it could convey the
information successfully in a real-life decision-making
setting. This is particularly important because in
Australia, among other countries, women interact dir-
ectly with a screening service, often bypassing any discus-
sion with a healthcare provider.
In the present study, we developed a decision aid for
women facing their initial decision about participation
in mammography screening. The information presented
includes the main beneﬁt and harms of screening
(breast cancer mortality reduction, false positives and
overdetection). The goal was to produce materials that
we could then use in a randomised trial to assess
whether information on overdetection makes a differ-
ence to women’s views and decisions about screening,17
with the potential for future adaptation into a resource
suitable for distribution within organised screening pro-
grammes. This paper describes the development and
preliminary evaluation of the decision aid.
METHODS
Overview of decision aid development and evaluation
Figure 1 depicts the stages of this project. Stage 1
included the design of a decision aid informed by our
focus group study,15 previous decision aid work18 19 and
other relevant literature, followed by an iterative piloting
and revision process involving user testing and expert
feedback. Then we created a control decision aid omit-
ting the overdetection content. In stage 2, the materials
underwent preliminary evaluation using a telephone
questionnaire and were subsequently revised to produce
ﬁnal versions. Stage 3 is a randomised trial comparing
the two decision aids.17 This paper reports stages 1 and 2.
Project team
Decision aid design and revisions involved a multidiscip-
linary team with expertise in the clinical, psychosocial
and epidemiological aspects of breast screening and
experience in developing tools to support health
decision-making. The team incorporates lay perspectives
from a health consumer organisation representative
(similar to our target audience in age and gender) and
an experienced independent citizen advocate. We
worked with a graphic designer to produce the booklets.
Evidence base for quantitative outcome information
The evidence to inform the decision aid content is from
an updated version (manuscript in preparation) of a
published model of breast screening outcomes for
women in Australia.20 The model incorporates estimates
of the breast cancer mortality reduction from screening
and of overdetection. Estimates were derived from a
meta-analysis of effects found in randomised trials,6
adjusted to reﬂect the impact of attending screening
regularly (not just being invited).21 These were applied
to current Australian incidence and mortality data to
quantify cumulative outcomes of biennial screening
from age 50 to 69 versus no screening over this period.
The 20-year cumulative likelihood of a false positive
result was modelled from current Australian breast
screening data.
Key design features
Offering choice
Unlike conventional screening materials encouraging
uptake,5 12 the decision aid is framed as a resource pro-
viding information to support women in choosing
whether to have screening or not.
Communicating outcome probabilities using visual formats
Quantitative screening outcome information is stated
transparently using absolute frequencies with a clearly
speciﬁed reference class.22 The expected frequency of
each outcome is illustrated by an icon array—a visual
graphic display representing the numerator and denom-
inator together via differently coloured ﬁlled circles
arranged in a matrix. As recommended by the
International Patient Decision Aids Standards,23 icon
arrays are formatted consistently and share a common
reference class: 1000 women screened for 20 years.
A summary table concludes the decision aid, bringing
together key information already presented to facilitate
comparison between the options (screening vs not
screening) in terms of the numbers of women dying
from breast cancer and experiencing screening harms.
Such summaries are generally a well utilised and liked
feature of decision tools.24
2 Hersch J, et al. BMJ Open 2014;4:e006016. doi:10.1136/bmjopen-2014-006016
Open Access
Plain language
We followed suggestions for making information easy to
understand across literacy levels.25 The Flesch-Kincaid
readability score of 7.85 indicates that the booklet is suit-
able for readers at the seventh to eighth grade level.
A glossary deﬁnes medical terms, and earlier ﬁndings
guided word choice—for example, we use overdetection
as focus groups showed that overdiagnosis may be con-
fused with misdiagnosis.15
Communicating the novel concept of overdetection
As the concept of overdetection is expected to be new to
most readers, we created a simple conceptual illustration
based on a slide that helped our focus group partici-
pants.15 It depicts two alternative scenarios that could
happen to a hypothetical woman with asymptomatic
breast cancer: one with screening (and consequent
cancer diagnosis and treatment); and one without screen-
ing. In both scenarios, the woman lives to age 85 and
dies of heart disease. This is intended to help readers
understand how screening can lead to overdetection of
cancers that would never cause harm.
A question-and-answer section describes evidence for
overdetection and how and why breast cancer is treated,
and addresses potential misunderstandings that the
novel information could raise.15
Stage 1 interviews
Participants
Stage 1 involved 15 participants. Six women were
recruited by convenience sampling among our contacts;
they were not familiar with the study but were friends,
relatives or partners of the project team or of colleagues.
Another nine women were from a database of potential
research participants originally identiﬁed through
random sampling of Sydney telephone numbers as part
of the recruitment for our previous study.15 These
women had expressed interest in participating in our
research should a suitable opportunity arise, but were
unable to join the scheduled focus group sessions. We
obtained ethics approval to recontact them and invite
them to take part in decision aid piloting.
Table 1 shows the stage 1 sample characteristics. All
women spoke English at home, none had a personal
history of breast cancer, and about half had been screened.
Procedure
JH conducted audiorecorded interviews (35–50 min)
between February and October 2013. Participants were
sent the draft decision aid to read beforehand.
Interviews were conducted face to face (n=13) at
women’s homes or at the university, or by telephone
(n=2). The semistructured interviews focused on a set of
purpose-designed questions to assess comprehension of
Figure 1 Flow chart of decision
aid development and evaluation
process.
Table 1 Stage 1 participant characteristics (n=15)
Characteristics No. of women
Age (years)
43–47 4
48–49 7
50–59 4
Education
School only 3
Diploma or trade certificate 3
University degree 9
Mammography screening history
Screened at least once 8
Never screened 7
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key content and preferences regarding presentation. We
incorporated a standard teach-back technique, asking
women to describe in their own words what selected
parts of the booklet were trying to communicate. The
interviewer noted women’s responses and raised prob-
lematic aspects in team discussions where successive
modiﬁcations were considered.
Expert review
We sought feedback on the draft decision aid from two
independent experts not involved in the project: a com-
munication expert (researcher and journalist) and a
clinical expert (oncologist and clinical epidemiologist).
The ﬁrst review emphasised the importance of being
‘upfront’ about uncertainty in the quantitative informa-
tion. We had included this acknowledgement at the end
of the booklet but subsequently moved it to the intro-
duction: ‘The numbers presented are the best available
estimates based on the latest research. They may need to
be reviewed in the future when new information
becomes available.’ The second review highlighted that
some icon arrays presented outcome categories that
were subsets of others (eg, false positives leading to biop-
sies vs all false positives) and this was not always clear.
Table 2 Content of final decision aids, with italics for items found only in intervention (Int.)
Section Summary of content
Title Breast cancer screening: It’s your choice
Subtitle New information to help women aged about 50 to make a decision
Introduction Why is there a decision to make about having breast cancer screening?
What is the purpose of this booklet?
What is breast cancer screening?
Box: Screening is for women without symptoms
Making my choice about screening: Is this information relevant for me?
What can I consider to help me make my decision?
Box: There are 2 important things to know [Int.: 3 important things]
Numbers presented are best available estimates
Mortality benefit Screening leads to fewer women dying from breast cancer
Explanation about the lower number of women who die of breast cancer
Icon array of 1000 women screened over 20 years, showing how many:
▸ avoid dying from breast cancer because of screening
▸ still die from breast cancer in spite of screening
Overdetection Screening leads to finding some breast cancers that are not harmful
Explanation about overdetection and consequent overtreatment
Icon array of 1000 women screened over 20 years, showing how many:
▸ experience overdetection
▸ are diagnosed with breast cancer that is not overdetection
Conceptual illustration contrasting scenarios with vs without screening
Box: Putting together breast cancer mortality benefit vs overdetection
False positive results Screening leads to some false positive results and extra testing
Explanation about false positive screening results
Icon array of 1000 women screened over 20 years, showing how many:
▸ have a false positive with a biopsy
▸ have a false positive with other extra tests
Questions you may have What happens after an abnormal screening result?
How is overdetection different from false positives?
How is breast cancer treated?
If diagnosed, can I wait and see before I decide about treatment?
Can I screen using ultrasound or some other test, or combine tests?
How do we know that overdetection exists?
Making a choice: summary Table comparing screening vs no screening, addressing (over 20 years):
▸ What are the chances of dying from breast cancer?
▸ What are the chances of experiencing overdetection?
▸ What are the chances of having a false positive and extra testing?
▸ What would I need to do?
Key scientific articles
Glossary List of 15 medical terms and what they mean [Int.: 16 terms]
Closing information Further information sources (doctor, Cancer Council Helpline, websites)
This booklet was developed in 2013 by STEP, University of Sydney
If you have any questions about this booklet, please call study helpline
University of Sydney logo
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We revised the diagrams to improve clarity and balance.
For example, where we had already presented (i) the
total number of breast cancers diagnosed and (ii) the
number within that total which represented overdetec-
tion, we then added to the text (iii) the complementary
number of cases that were not instances of
overdetection.
Intervention and control versions of decision aid
Table 2 shows the content of the ﬁnal decision aids (at
the end of stage 2). The control version was created at
the end of stage 1 by deleting all overdetection-related
material (two pages) from the intervention decision aid.
The sections on beneﬁt and false positives remained
identical across versions in content and format. The
booklets were printed in B5 size (176×250 mm).
Stage 2 interviews
In stage 2, 34 additional women were interviewed about
the revised decision aids. This took place within a pilot
study conducted between October and December 2013
to test the feasibility of recruitment, randomisation and
data collection procedures ahead of the randomised
trial (stage 3). Procedures are described in detail else-
where17 and outlined brieﬂy below.
Participants
We recruited a community sample of women facing real
decisions. The New South Wales state electoral register
extracted a random selection of women aged 48–49 (ie,
approaching age 50, when Australian women are rou-
tinely invited to breast screening). We sent a database of
names and telephone numbers to the Hunter Valley
Research Foundation (HVRF), an independent non-
proﬁt organisation. HVRF interviewers telephoned
women, invited those eligible to participate, and
obtained oral consent. The interviewers were not aware
of the randomisation sequence. Exclusion criteria were:
personal history of breast cancer; increased risk of breast
cancer; any mammogram in the past 2 years; or insufﬁ-
cient ﬂuency in English.
Table 3 shows stage 2 sample characteristics. Although
36 women were randomised, 2 (6%) were lost to
follow-up—one in each arm.
Procedure
Using a computer random number generator, partici-
pants were randomised to be sent either the intervention
or control decision aid by post. Participants had been
told that they would receive one of two versions of the
booklet, but they were not aware of how the versions dif-
fered or which was the intervention arm. Around 3 weeks
later, a trained HVRF interviewer conducted a structured
telephone interview (15–20 min) measuring decision aid
acceptability using rating scales,19 26 knowledge using
items adapted from previous work,15 26 and other trial
outcomes17 that are beyond the scope of this paper.
RESULTS
Communication issues and corresponding revisions
The stage 1 (qualitative) and 2 (quantitative) interviews
together highlighted several important challenges in the
communication of information about unfamiliar aspects
of screening—speciﬁcally, the risk of overdetection and,
more broadly, the possibility of harm and relevance of
an informed choice approach. We modiﬁed the decision
aid drafts to address these issues, as outlined in table 4
and detailed below.
Table 4 Key issues identified during the piloting process, with corresponding revisions made
Key issues Revisions to address issues
Lack of familiarity with cancer screening being
framed as a choice
Emphasise there is a personal decision to be made, with no right or
wrong answer
Overdetection not understood as a harm of
screening
Increase salience of consequences of overdetection by adding
information on treatments and side effects
Confusion about distinction between overdetection
and false positives
Emphasise distinction through modifications to wording, ordering and
formatting; add a question and answer addressing this point
Relationship between risk of overdetection and
chance of benefit not being well understood
Add box explicitly saying more women experience overdetection than
avoid dying from breast cancer
New and complex material Increase text size and make more use of white space
Table 3 Stage 2 participant characteristics (n=34)
Characteristics
No. of
women
Age
48 12
49 22
Education
Intermediate school certificate 10
Higher school certificate or trade certificate 7
Diploma or advanced diploma 7
University degree, graduate diploma or
graduate certificate
10
Mammography history (part of eligibility criteria)
Any mammogram in the past 2 years 0
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Lack of familiarity with screening information framed around
choice
The stage 1 interviews showed women were unfamiliar
with screening participation being explicitly framed as
an option they could choose to either take up or not—
as one woman noted,
People aren’t used to being given information to make a
balanced choice, you know. We are used to being given:
go and do this, it’s good for you…But to be treated like
someone with a free will and being given the possession
of the facts, we don’t get treated like that very often in
public life. So… we’re being treated like grownups for once.
Therefore, the underlying purpose—to encourage a
personal decision—needed to be made explicit. As this
issue had arisen with previous screening decision
aids,19 27 our initial draft tried to address it by posing a
question in the title (‘Should I…?’) and stating in the
opening paragraph that the ‘booklet is designed to help
you make an informed choice about whether you would
prefer to have screening or not.’ However, ﬁndings from
the ﬁrst few interviews led us to strengthen this by adding
‘there is no right or wrong answer about whether to have
breast screening. It is a matter of what you believe is the
right choice for you.’ We also renamed the booklet
‘Breast cancer screening: It’s your choice’ and modiﬁed
the subtitle to include ‘information to help women make
a decision’ rather than ‘information to consider’. These
aspects were identical for the control version.
Overdetection not understood as a harm
An obvious factor contributing to women’s confusion
about why the booklet presents screening as an interven-
tion with pros and cons was their lack of prior awareness
of overdetection. Learning about what one woman
described as “quite a complicated idea” for the ﬁrst
time, it appeared difﬁcult for some women to grasp
whether and why overdetection may be considered a
negative outcome. A stage 1 interviewee said, “I just
don’t know if overdetection is seen as being a problem”
and “I don’t understand the anxiety about overdetec-
tion, and why it’s being ﬂagged as an issue”. Another
stated that “overdetection is not necessarily a harm or a
bad thing”, while a third said, “the overdetection part
didn’t really make me feel that uncomfortable because
I’m the sort of person, I think, that would rather know
and have it treated”. Although the initial draft had men-
tioned various breast cancer treatment modalities and
acknowledged that these involve side effects, we
expanded this into a new section providing a short
description of the mechanism of each treatment and
several common side effects. This aimed to help women
better understand the implications of being overdiag-
nosed and the likely course of treatment that may follow
a diagnosis.
Confusion about distinction between overdetection and false
positive screening results
In the stages 1 and 2 interviews, some women showed
confusion regarding the concepts of overdetection and
false positives—for example, “What’s the difference
between—so, the overdetection is the false positive? Is it
the same thing? …That’s the confusion that I’ve had…
I didn’t quite understand that from reading that…
I think I was just assuming it was all the same thing.”
Although the initial draft already had these two out-
comes presented under separate headings and listed on
separate lines in the summary table, we revised the deci-
sion aid within stage 1 to try and clarify this point by
explicitly numbering the outcomes in the section head-
ings and summary table. We also added a statement
to the introduction—“There are 3 important things to
know: …”—brieﬂy listing as 1, 2 and 3 the outcomes to
be covered in the booklet (ie, breast cancer mortality
beneﬁt, false positives and overdetection).
Despite these efforts, the stage 2 interviews demon-
strated the persistence of some confusion between the
concepts, leading us to take several additional steps to
further clarify our presentation of this information. First,
to draw attention to the aforementioned ‘3 important
things’ statement, we put a box around it. Second, we
tried to encourage attention to the overdetection
content by ﬂagging it as ‘new’ information. Third, we
moved this section to an earlier position in the booklet,
ahead of the false positives section. Fourth, we made
minor modiﬁcations to the text explaining the two con-
cepts, including slight wording changes and use of bold
font to emphasise key phrases (eg, in false positives
‘there is no cancer’). Finally, we added a new item to the
question and answer section to explicitly address this
point: ‘How is overdetection different from false
positives?’
Relationship between risk of overdetection and chance of
benefit not well understood
The stage 2 interviews included questions to assess
whether women had understood the key facts. One such
point related to which outcome would affect more
women—overdetection or avoidance of a breast cancer
death. This was asked in a ‘true or false’ format, which a
majority of respondents answered incorrectly. In the
light of this, we added a new box following a presenta-
tion of the beneﬁt and overdetection information,
entitled ‘Putting it together’. Here we restated for both
outcomes the absolute numbers per 1000 women
screened over 20 years, noting explicitly ‘that means
more women experience overdetection than avoid dying
from breast cancer.’
Communication of new and complex material
The piloting process highlighted the challenge readers
faced to absorb what one woman called “quite compli-
cated information”. Another remarked, “I had to read it a
few times… It was quite clear when I went back to it. But
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initially it was quite overwhelming.” To improve overall
ease of reading, in the ﬁnal revision we increased the
font size and spaced out the intervention content over 11
pages rather than the original 8. We modiﬁed the control
version accordingly (changing from 6 pages to 8).
Booklet acceptability
Stage 1 (qualitative)
Overall, stage 1 participants reacted positively towards
the decision aid. Although some aspects were evidently
challenging to understand (see previous section), all 15
women said they found most things or everything clear.
The graphical presentation of quantitative information
was generally liked—for example, “It was really clear, it
really explained it well. I’m a visual person. I mean, if
there’s ﬁgures I tend to go blank. But when you actually
see that represented by dots it’s very easy to
understand.” Every participant regarded the decision
aid as at least a little helpful, with about half saying it
was very helpful. Reading about the downsides of screen-
ing—“being told the other half of the picture”—was
thought-provoking. As one woman said, “It certainly did
make me think… it made me reﬂect… really this is
calling for a decision one way or another, and what will
I do when I’m 50”. Nonetheless, many of the women
expressed appreciation for the opportunity to become
better informed, and all but one would recommend
the resource to others facing the decision—for
example, “because it’s got information that people
need to know… I wish that I’d had that information
when I was turning 50… it would have been good to
know that, at the start. To be prepared and to have that
understanding, so I think it’s really good that this is out
there.”
Table 5 Acceptability of intervention and control decision aids (stage 2)
Intervention Control
n=16 n=18
About how long did you spend reading the booklet? (free response)
Median 12.5 min 10 min
How much of the information in the booklet was new to you?
None 0 1
Some 9 13
Most 6 4
All 1 0
How would you rate the length of the booklet?
Much too long 0 0
A little too long 3 4
Just about right 13 13
A little too short 0 1
Much too short 0 0
How balanced did you find the booklet?
Clearly slanted towards screening 5 2
A little slanted towards screening 1 6
Completely balanced 6 6
A little slanted away from screening 4 3
Clearly slanted away from screening 0 1
You found the information in the booklet clear and easy to understand
Strongly agree 6 12
Agree 7 5
Neither agree nor disagree 0 0
Disagree 3 1
Strongly disagree 0 0
You found the booklet helpful in making your decision about breast screening
Strongly agree 5 5
Agree 7 6
Neither agree nor disagree 1 3
Disagree 3 3
Strongly disagree 0 1
You would recommend this booklet to other women thinking about screening
Strongly agree 6 8
Agree 6 6
Neither agree nor disagree 2 3
Disagree 2 1
Strongly disagree 0 0
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Stage 2 (quantitative)
Table 5 presents quantitative acceptability data from
stage 2 interviews on the intervention and control deci-
sion aids. The majority of participants (76%) considered
their booklet just about right in length, with the remain-
der tending to say it was a little too long, and most
(76%) would recommend the decision aid to others.
Women found both booklets clear and easy to under-
stand (intervention 81%, control 94%) and helpful in
making their screening decision (75% and 61%, respect-
ively). Responses to the question about how much of the
information was new to the reader largely fell into the
categories ‘some’ and ‘most’, with group differences
apparently reﬂecting the additional new content (ie,
overdetection) in the intervention booklet. A question
about whether the booklet was balanced or slanted
towards or away from screening elicited a range of
responses in both groups (see table 5).
DISCUSSION
This paper describes the development and preliminary
evaluation of a decision aid designed to support women
to make informed decisions about breast screening. The
piloting process described here enabled us to explore
responses to successive drafts of the materials among
our intended audience. User testing with women
approaching the age of invitation to screening showed
that the decision aid could be read in a reasonable time
(10–15 min) and was generally received positively. Most
of the qualitatively interviewed women liked the graph-
ical presentation style used for the numerical informa-
tion, and considered it helpful to be able to “visually
scan the information”. As overdetection was the most
novel element of the content, our particular interest in
this study was examining whether women could compre-
hend this information and exploring how they reacted
to the presentation of screening downsides. The
purpose of undertaking the two stages of piloting prior
to more formal evaluation17 was to identify where there
was room for improvement and to modify our materials
accordingly.
We found that the main conceptual point of confusion
around overdetection related to understanding how it is
distinct from false positive screening results. While both
outcomes represent harms of screening, overdetection
has more serious implications for those affected. By
adding an item to the question and answer section
(‘How is overdetection different from false positives?’),
we have acknowledged that there is potential for confu-
sion and provided a concise statement underscoring
where the contrast lies. This leads to a question about
how breast cancer is treated (also an addition after
initial piloting), aiming to draw the reader’s attention to
the consequences of overdetection by highlighting some
of the common side effects of the main treatment
modalities. As in our focus group study,15 for some quali-
tative interview participants it was not clear why
overdetection would be considered a negative outcome
of screening, whereas others who had more experience
with cancer treatment (albeit indirectly) grasped this
more readily. This reinforces the importance of decision
aids including some description of what it may be like to
experience the consequences of choosing particular
options, which may help a reader clarify her values.28
In terms of the magnitude of overdetection, we con-
sider it important for readers to understand the ‘bottom
line’ that overdetection occurs more frequently than
prevention of death from breast cancer. However, a ‘true
or false’ knowledge item about this was answered poorly
in stage 2. As the different outcomes were shown on sep-
arate icon arrays, it may have been difﬁcult for readers
to connect and compare the beneﬁt and overdetection
ﬁgures. In the revised intervention, we tried to make
this relationship clearer by reinforcing the visual depic-
tions with an added short text box, thus giving the
reader key information in two complementary ways. The
ﬁnal version also has the icon arrays for beneﬁt and
overdetection on facing pages, which may make the
comparison more salient.
It was also evident from the qualitative interviews that
the decision aids—with their neutral presentation of
beneﬁt and harm information and framing of a choice
between screening and not screening—did not match
readers’ expectations for screening messages, which are
typically persuasive in tone and intent. Similar issues have
been reported in previous research on informed choice
in screening.16 27 29 30 This underscores the need for
screening decision aids to start by clearly explaining their
purpose and why there is a decision to make, as ours did.
The strengths of this project include the rigorous
staged approach to developing and evaluating the inter-
vention. Our initial design built on a comprehensive
qualitative study that explored responses to overdetec-
tion in 50 women15 together with our previous experi-
ence in producing and trialling cancer screening
decision aids.18 26 31 We used an iterative process of
pilot-testing, combining both qualitative and quantitative
data, and revised our materials successively according to
the ﬁndings. Such an approach is recommended19 25 32
as it facilitates a thorough exploration of problematic
aspects and careful testing of potential solutions.
Decisions about initial design and subsequent revisions
were undertaken in consultation with an experienced
multidisciplinary research team, incorporating input
from laypersons as well as independent experts. Possible
limitations are the inclusion of some women recruited
via convenience sampling (n=6) and the fact that stage 1
participants were somewhat varied in age and screening
history compared with the speciﬁc target population for
our decision aids. However, for the further evaluation in
stage 2 (n=34), we recruited directly from our target
population, and these women read our booklets within a
real-life decision-making setting.
We have produced these decision aids for the pur-
poses of a population-based randomised controlled trial
8 Hersch J, et al. BMJ Open 2014;4:e006016. doi:10.1136/bmjopen-2014-006016
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(stage 3) examining how information about overdetec-
tion affects women’s decision-making about breast
screening.17 Trial participants will receive one of our
decision aids in addition to other information materials
in current use locally.33 As such, we have not included
practical information such as the procedural aspects of
having a mammogram, which would need to be added
in order to produce a stand-alone resource. Although
our current focus is on introducing to women the novel
concept of overdetection and overtreatment, as public
understanding increases over time, future decision aid
developers might consider also trying to address the dif-
ﬁcult issues of how screening may affect the extent of
treatment women receive and the risk of dying from all
causes. Our decision aids have been designed to be
accessible to people with an average level of reading
ability, and further work would be required to adapt the
materials to ensure that they are suitable for lower-
literacy groups and culturally diverse populations.
Ultimately, this work will help address the increasingly
recognised responsibility for cancer screening services to
provide evidence-based beneﬁt and harm information to
people in a clear, transparent way.5–7 34
Implications and conclusions
The concept of overdetection is complex and new to the
public, and people may ﬁnd the issue hard to under-
stand. In our efforts to communicate with women about
overdetection in breast screening, we have found it
important to make clear why overdetection may be con-
sidered a concern by explaining the associated conse-
quences in terms of unnecessary treatments that can
cause harm. Related to this is the need to differentiate
very clearly between overdetection and false positives,
which we have identiﬁed as a common source of confu-
sion. Encountering balanced information about screen-
ing rather than a persuasive message is contrary to
people’s expectations. Results of the decision aid trial
that is currently underway17 will indicate whether we
have succeeded in overcoming these challenges and
communicating effectively about overdetection.
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